Commercially available noninvasive screening tests for colorectal cancer—a fecal
immunochemical test (FIT) and the multi-target stool DNAtest (mt-sDNA)—are equally effective
for screening patients with early-stage colorectal cancer. However, a FIT costs about one-fifth
of the multi-target DNA test, according to new study results presented during the Scientific
Forum at the American College of Surgeons Clinical Congress 2022.
Citation:
Rao, PK et al. Comprehensive Cost Implications of Commercially Available Non-invasive Colorectal Cancer Screening Modalities: Results of A Large National Insurer Claims Database Analysis, Scientific Forum, American College of Surgeons Clinical Congress 2022.
Study authors
:
Pavan K. Rao, MD (appearing in this video); Casey J. Allan, MD; Patrick L. Wagner, MD,
FACS; David L. Bartlett, MD, FACS; and Sricharan Chalikonda, MD, MHA, FACS
Allegheny Health Network, Pittsburgh, Pennsylvania
Samantha Falls, DO; Stacey Shipley, BA; and Katie Farah, MD
Allegheny Health Network, Wexford, Pennsylvania
About American College of Surgeons:
The American College of Surgeons (ACS) is a scientific and educational association of surgeons that was founded in 1913 to improve the quality of care for the surgical patient by setting high standards for surgical education and practice and is headquartered in Chicago, IL. The College is a surgical society dedicated to promoting the highest standards of surgical care through education of, and advocacy for, its Fellows and their patients, and to safeguarding standards of care in an optimal and ethical practice environment.
Get more ACS:
YouTube: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
Colorectal Cancer Screening: A Less Expensive Noninvasive Alternative | Clinical Congress | ACS
[ Ссылка ]
ACS
[ Ссылка ]
